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Introduction {#sec005}
============

Hepatocellular carcinoma (HCC) remains one of the most invasive cancers in humans, mostly occurring in patients with chronic liver disease, and the third leading cause of cancer-related death throughout the world \[[@pone.0228857.ref001]\]. Although its causes, prevention, and treatment strategies are recommended in guidelines, HCC is expected to become a pressing health problem facing the world in the coming decades \[[@pone.0228857.ref001], [@pone.0228857.ref002]\] Although researchers are making strides in HCC monitoring and treatment, there has been little improvement in survival in patients with HCC. In the United States, the 5-year survival rate of patients with HCC is still less than 12% \[[@pone.0228857.ref003]\]. The effective therapies are very limited for advanced HCC whose the survival rate decreased significantly \[[@pone.0228857.ref004]\], while there are several available treatments for the management of HCC with early stage, such as radical resection or liver transplantation, where 5-year survival rate of HCC patients who met the Milan criteria (single nodule \< 5cm or three nodules diameter \< 3cm) after liver transplantation was more than 70% \[[@pone.0228857.ref005], [@pone.0228857.ref006]\]. Therefore, the early discovery of HCC might be very important, and it is reported that early detection of HCC can improve the clinical outcomes \[[@pone.0228857.ref007]\]. Based on the evidence of benefits from early detection of HCC, the guidelines of both American Association, Asian Pacific Association, and Japan Association recommend HCC monitoring in high-risk patients for early diagnosis of HCC \[[@pone.0228857.ref008]--[@pone.0228857.ref011]\].

The alpha-fetoprotein (AFP) in serum is currently available diagnostic marker for HCC discovery. As for patients with chronic liver disease, a sustained increase in AFP serum level was shown to be one of the risk factors of HCC and has been used to help identify high-risk subgroup of chronic liver disease \[[@pone.0228857.ref012]\]. In patients with liver cirrhosis, fluctuations in AFP levels may reflect the sudden onset of viral hepatitis, the deterioration of the potential liver disease, or the development of HCC \[[@pone.0228857.ref013]\]. Besides, the level of AFP was reported to interact with some molecular subtypes such as EpCAM positive in invasive HCC \[[@pone.0228857.ref014]--[@pone.0228857.ref016]\]. It is established that multiple factors could contribute to the AFP level, which increases the difficulty of identifying the threshold. When the cutoff value of AFP was 20 ng/ml, the detection showed relatively good sensitivity with poor specificity, while when the cutoff value was 200 ng/ml, the discovery performed high specificity, but the sensitivity decreased significantly \[[@pone.0228857.ref017]\]. In 2001 and 2017 diagnostic staging standard of HCC in China, AFP 400 ng/mL was used as the diagnostic threshold \[[@pone.0228857.ref018]\]. However, a meta-analysis \[[@pone.0228857.ref019]\] shows that the diagnostic efficiency of AFP ≥ 200 ng/mL may be higher, partly because some of the early HCC \[[@pone.0228857.ref020]\] may be missed in the population with low concentration of AFP (20 to 200 ng/mL) if 400 ng/mL is still used as the criteria in HCC screening. Therefore, up to now, the optimal threshold of AFP for the diagnosis of HCC is still controversial \[[@pone.0228857.ref021]--[@pone.0228857.ref023]\].

In addition, it has been reported that AFP combined with ultrasound detection might improve the detection rate of HCC \[[@pone.0228857.ref024]\]. Both American Association for the Study of Liver Disease (AASLD) and European Association for the Study of the Liver (EASL) suggest that it is necessary to monitor HCC in high-risk patients partly by abdominal ultrasonography every six months, but there exists argument in the use of AFP as an auxiliary monitoring test and there is no identified threshold of AFP when the combination of AFP and ultrasound is used to monitor HCC \[[@pone.0228857.ref025], [@pone.0228857.ref026]\].

Therefore, it is particularly important to explore the optimal screening and diagnostic threshold of serum AFP with or without ultrasound for early diagnosis of HCC. The purpose of this study was to identify the optimal diagnostic threshold of serum AFP by systematic review and meta analysis. This article was performed based on Meta-Analysis of Observational Studies in Epidemiology (MOOSE) and reported in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) statement \[[@pone.0228857.ref027], [@pone.0228857.ref028]\], and Qualitu assessment for studies of diagnostic accuracy (QUADAS-2) was used to evaluate the quality of diagnostic test \[[@pone.0228857.ref029]\].

Results {#sec006}
=======

We retrieved 29,828 records from databases search, and assessed 21,464 records after deleting the duplication, and finally 59 original articles in terms of AFP alone and one systematic review in terms of AFP in combination with ultrasound \[[@pone.0228857.ref030]--[@pone.0228857.ref087]\] were enrolled for data synthesis, as is shown in **[Fig 1](#pone.0228857.g001){ref-type="fig"}**. This systematic review finally yielded information on a total of 11,731 HCC cases confirmed by histomorphology and 21,972 control cases without HCC.

![Flow diagram of study selection.](pone.0228857.g001){#pone.0228857.g001}

Basic information and quality assessment {#sec007}
----------------------------------------

The basic information of the included studies was shown in **[Table 1](#pone.0228857.t001){ref-type="table"}**. In all, we summarized the results from 4 studies using a AFP threshold of 400 ng/mL, and from 4 studies using a AFP threshold of 200 ng/mL, and 46 studies using a AFP threshold of 20--100 ng/mL. As for the sample, the serum was used to detect the AFP by forty-three studies, while the remaining used plasma. The included 59 researches were conducted in diverse countries, including China (n = 15), USA (n = 11), Japan (n = 9), Korea (n = 8), Egypt (n = 5), Italy (n = 2), Thailand (n = 2), France (n = 2), South Africa (n = 1), Turkey (n = 1), India (n = 1), Germany (n = 1), Indonesia (n = 1), and Australia (n = 1). Thirty-seven studies used samples from Asian while twenty-three studies used samples from Caucasian. As for the etiology of HCC, 16 studies \[[@pone.0228857.ref049], [@pone.0228857.ref051], [@pone.0228857.ref052], [@pone.0228857.ref055], [@pone.0228857.ref057], [@pone.0228857.ref059], [@pone.0228857.ref062], [@pone.0228857.ref064], [@pone.0228857.ref066], [@pone.0228857.ref069], [@pone.0228857.ref073], [@pone.0228857.ref075], [@pone.0228857.ref079]--[@pone.0228857.ref081], [@pone.0228857.ref086]\] only covered HBV or HCV hepatitis, one study was not available, and the remaining 42 studies \[[@pone.0228857.ref030]--[@pone.0228857.ref048], [@pone.0228857.ref050], [@pone.0228857.ref053], [@pone.0228857.ref054], [@pone.0228857.ref056], [@pone.0228857.ref058], [@pone.0228857.ref060], [@pone.0228857.ref061], [@pone.0228857.ref063], [@pone.0228857.ref065], [@pone.0228857.ref068], [@pone.0228857.ref070]--[@pone.0228857.ref072], [@pone.0228857.ref074], [@pone.0228857.ref076]--[@pone.0228857.ref078], [@pone.0228857.ref082]--[@pone.0228857.ref084], [@pone.0228857.ref086], [@pone.0228857.ref087]\] were mix which included HBV infection, HCV infection, alcohol and others. Shown were the estimates of sensitivity, specificity, true positive, false positive, false negative, true negative in terms of AFP in HCC diagnosis in the **[Table 2](#pone.0228857.t002){ref-type="table"}**. The quality assessment by QUADAS-2 tool revealed a overall judgment of at low risk of bias for the included studies, which was shown in **[S3 Table](#pone.0228857.s004){ref-type="supplementary-material"}**. Specifically, domain of patient selection, index test, and flow and timing showed a low risk of bias, domain of reference standard showed a conclusion of potential for bias exits, and the applicability concerns were rated as low.

10.1371/journal.pone.0228857.t001

###### Characteristics of studies included in the meta-analysis.

![](pone.0228857.t001){#pone.0228857.t001g}

  Study                                           Year   Country        HCC/controls   Etiology   Assay type   Cut-off (ng/mL)   Sample type
  ----------------------------------------------- ------ -------------- -------------- ---------- ------------ ----------------- -------------
  King et al. \[[@pone.0228857.ref030]\]          1989   South Africa   98/120         MIX        ELISA        20                Serum
  Takikawa et al. \[[@pone.0228857.ref031]\]      1992   Japan          116/512        MIX        ELISA        20                Plasma
  Fujiyama et al. \[[@pone.0228857.ref032]\]      1992   Japan          200/197        MIX        ELISA        20                Plasma
  Suehiro et al. \[[@pone.0228857.ref033]\]       1994   Japan          185/118        MIX        ELISA        20                Plasma
  Grazi et al. \[[@pone.0228857.ref034]\]         1995   Italy          111/116        MIX        ELISA        20                Serum
  Nomura et al. \[[@pone.0228857.ref035]\]        1999   Japan          36/49          MIX        ELISA        20                Serum
  Sassa et al. \[[@pone.0228857.ref036]\]         1999   Japan          61/134         MIX        ELISA        20                Serum
  Ishii et al. \[[@pone.0228857.ref037]\]         2000   Japan          29/705         MIX        ELISA        20                Serum
  Cui et al. \[[@pone.0228857.ref038]\]           2002   China          60/30          MIX        ELISA        20                Serum
  Shimizu et al. \[[@pone.0228857.ref039]\]       2002   Japan          56/34          MIX        ELISA        20                Serum
  Cui et al. \[[@pone.0228857.ref040]\]           2003   China          120/90         MIX        ELISA        20                Serum
  Marrero et al. \[[@pone.0228857.ref041]\]       2003   USA            55/104         MIX        ELISA        20                Serum
  Marrero et al. \[[@pone.0228857.ref042]\]       2005   USA            144/108        MIX        ELISA        99                Serum
  Wang et al. \[[@pone.0228857.ref043]\]          2005   China          61/64          MIX        ELISA        20                Serum
  Kim et al. \[[@pone.0228857.ref044]\]           2006   Korea          62/60          MIX        CH           70.4              Plasma
  Volk et al. \[[@pone.0228857.ref045]\]          2007   USA            84/169         MIX        ELISA        23                Serum
  Durazo et al. \[[@pone.0228857.ref046]\]        2008   USA            144/96         MIX        ELISA        25                Serum
  Beneduce et al. \[[@pone.0228857.ref047]\]      2008   Italy          33/31          MIX        ELISA        20                Serum
  Wang et al. \[[@pone.0228857.ref048]\]          2009   USA            164/113        MIX        ELISA        NK                Serum
  Hu et al. \[[@pone.0228857.ref049]\]            2009   China          31/93          HBV        ELISA        36                Serum
  Marrero et al. \[[@pone.0228857.ref050]\]       2009   USA            419/417        MIX        ELISA        20                Serum
  Yoon et al. \[[@pone.0228857.ref051]\]          2009   Korea          106/100        HBV        ELISA        20                Serum
  Sterling et al. \[[@pone.0228857.ref052]\]      2009   USA            74/298         HCV        ELISA        20                Serum
  Baek et al. \[[@pone.0228857.ref053]\]          2009   Korea          227/100        MIX        ELISA        20                Serum
  Yamamoto et al. \[[@pone.0228857.ref054]\]      2009   Japan          190/490        MIX        ELISA        20                Serum
  Mao et al. \[[@pone.0228857.ref055]\]           2010   China, USA     789/3428       HBV        ELISA        35                Serum
  Ozkan et al. \[[@pone.0228857.ref056]\]         2010   Turkey         75/83          MIX        ELISA        4.36              Serum
  Bessa et al. \[[@pone.0228857.ref057]\]         2010   Egypt          30/30          HCV        ELISA        69.5              Plasma
  Sharma et al. \[[@pone.0228857.ref058]\]        2010   India          70/38          MIX        ELISA        13                Serum
  Ishida et al. \[[@pone.0228857.ref059]\]        2010   Japan          141/143        HCV        ELISA        20                Serum
  Tian et al. \[[@pone.0228857.ref060]\]          2011   China          153/219        MIX        ELISA        13.6              Serum
  Shi et al. \[[@pone.0228857.ref061]\]           2011   China          55/107         MIX        ELISA        400               Serum
  Makarem et al. \[[@pone.0228857.ref062]\]       2011   Egypt          113/120        HCV        CH           43                Plasma
  Morota et al. \[[@pone.0228857.ref063]\]        2011   USA            70/34          MIX        ELISA        15                Serum
  Salem et al. \[[@pone.0228857.ref064]\]         2012   Egypt          30/40          HCV        ELISA        10.4              Serum
  Shang-1 et al. \[[@pone.0228857.ref065]\]       2012   Thailand       91/23          MIX        ELISA        20                Plasma
  Shang-2 et al. \[[@pone.0228857.ref065]\]       2012   USA            40/73          MIX        ELISA        20                Plasma
  Yang et al. \[[@pone.0228857.ref066]\]          2013   China          179/80         HBV        CH           20                Plasma
  Choi et al. \[[@pone.0228857.ref067]\]          2013   Korea          90/78          NA         ELISA        10                Serum
  Ertle et al. \[[@pone.0228857.ref068]\]         2013   Germany        164/422        MIX        ELISA        10                Serum
  Xu-1 et al. \[[@pone.0228857.ref069]\]          2014   China          2472/578       HBV        ELISA        20                Serum
  Xu-2 et al. \[[@pone.0228857.ref069]\]          2014   China          2472/578       HBV        ELISA        200               Serum
  Xu-3 et al. \[[@pone.0228857.ref069]\]          2014   China          2472/578       HBV        ELISA        400               Serum
  Chan-1 et al. \[[@pone.0228857.ref070]\]        2014   China          562/243        MIX        CH           10                Serum
  Chan-2 et al. \[[@pone.0228857.ref070]\]        2014   China          562/243        MIX        CH           200               Serum
  Chan-3 et al. \[[@pone.0228857.ref070]\]        2014   China          562/243        MIX        CH           500               Serum
  Gopal-1 et al. \[[@pone.0228857.ref071]\]       2014   USA            452/676        MIX        ELISA        20                Serum
  Gopal-2 et al. \[[@pone.0228857.ref071]\]       2014   USA            452/676        MIX        ELISA        200               Serum
  Gopal-3 et al. \[[@pone.0228857.ref071]\]       2014   USA            452/676        MIX        ELISA        400               Serum
  Lee et al. \[[@pone.0228857.ref072]\]           2014   Korea          120/40         MIX        ELISA        6                 Serum
  Nabih et al. \[[@pone.0228857.ref073]\]         2014   Egypt          35/34          HCV        CH           240               Plasma
  Song et al. \[[@pone.0228857.ref074]\]          2014   China          550/604        MIX        ELISA        21                Serum
  Costa et al. \[[@pone.0228857.ref075]\]         2015   France         75/75          HCV        ELISA        20                Plasma
  Poté et al. \[[@pone.0228857.ref076]\]          2015   France         85/43          MIX        ELISA        5                 Serum
  Chang et al. \[[@pone.0228857.ref077]\]         2015   China          363/1234       MIX        ELISA        20                Serum
  Gani et al. \[[@pone.0228857.ref078]\]          2015   Indonesia      59/47          MIX        ELISA        20.45             Serum
  Chimparlee et al. \[[@pone.0228857.ref079]\]    2015   Thailand       157/170        HBV        ELISA        20                Serum
  Fouad et al. \[[@pone.0228857.ref080]\]         2015   Egypt          25/25          HCV        ELISA        142               Serum
  Ge et al. \[[@pone.0228857.ref081]\]            2015   China          89/301         HBV        ELISA        6.79              Serum
  Yu et al. \[[@pone.0228857.ref082]\]            2015   China          134/347        MIX        CLEIA        20                Serum
  Jang et al. \[[@pone.0228857.ref083]\]          2016   Korea          208/193        MIX        ELISA        20                Plasma
  Roslyn et al. \[[@pone.0228857.ref084]\]        2016   Australia      86/258         MIX        CH           20                Serum
  Ji et al. cohort A \[[@pone.0228857.ref085]\]   2016   China          236/135        HBV        ELISA        20                Serum
  Ji et al. cohort B \[[@pone.0228857.ref085]\]   2016   China          200/97         HBV        ELISA        20                Serum
  Ahn-1 et al. \[[@pone.0228857.ref086]\]         2016   Korea          366/366        MIX        ELISA        20                Serum
  Ahn-2 et al. \[[@pone.0228857.ref086]\]         2016   Korea          366/366        MIX        ELISA        100               Serum
  Ahn-3 et al. \[[@pone.0228857.ref086]\]         2016   Korea          366/366        MIX        ELISA        200               Serum
  Ahn-4 et al. \[[@pone.0228857.ref086]\]         2016   Korea          366/366        MIX        ELISA        400               Serum
  Lim et al. \[[@pone.0228857.ref087]\]           2016   Korea          361/276        MIX        ELISA        20                Serum

MIX: the etiology including HBV infection, HCV infection, alcohol and others; ELISA: enzyme immunometric assay; CH: chemiluminescence; CLEIA: chemiluminescence enzyme immunoassay; NK = not known; NA: not available.

10.1371/journal.pone.0228857.t002

###### The indicators for HCC diagnosis were extracted from the included studies.
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  Study                                           Year   SE (%)   SP (%)   TP     FP    FN     TN
  ----------------------------------------------- ------ -------- -------- ------ ----- ------ ------
  King et al. \[[@pone.0228857.ref030]\]          1989   74       99       73     1     25     119
  Takikawa et al. \[[@pone.0228857.ref031]\]      1992   71       75       82     128   34     384
  Fujiyama et al. \[[@pone.0228857.ref032]\]      1992   51       97       102    6     98     191
  Suehiro et al. \[[@pone.0228857.ref033]\]       1994   65       72       120    33    65     85
  Grazi et al. \[[@pone.0228857.ref034]\]         1995   55       97       61     3     50     113
  Nomura et al. \[[@pone.0228857.ref035]\]        1999   58       76       21     12    15     37
  Sassa et al. \[[@pone.0228857.ref036]\]         1999   8        100      5      0     56     134
  Ishii et al. \[[@pone.0228857.ref037]\]         2000   62       78       18     155   11     550
  Cui et al. \[[@pone.0228857.ref038]\]           2002   59       85       35     4     25     26
  Shimizu et al. \[[@pone.0228857.ref039]\]       2002   57       63       32     13    24     21
  Cui et al. \[[@pone.0228857.ref040]\]           2003   93       63       112    33    8      57
  Marrero et al. \[[@pone.0228857.ref041]\]       2003   67       86       37     15    18     89
  Marrero et al. \[[@pone.0228857.ref042]\]       2005   30       96       43     4     101    104
  Wang et al. \[[@pone.0228857.ref043]\]          2005   59       77       36     15    25     49
  Kim et al. \[[@pone.0228857.ref044]\]           2006   54.8     100      34     0     28     60
  Volk et al. \[[@pone.0228857.ref045]\]          2007   62       91       52     15    32     154
  Durazo et al. \[[@pone.0228857.ref046]\]        2008   48       87       69     12    75     84
  Beneduce et al. \[[@pone.0228857.ref047]\]      2008   69       88       23     4     10     27
  Wang et al. \[[@pone.0228857.ref048]\]          2009   95       21       156    89    8      24
  Hu et al. \[[@pone.0228857.ref049]\]            2009   48       97       15     3     16     90
  Marrero et al. \[[@pone.0228857.ref050]\]       2009   59       90       247    42    172    375
  Yoon et al. \[[@pone.0228857.ref051]\]          2009   61       71       65     29    41     71
  Sterling et al. \[[@pone.0228857.ref052]\]      2009   55       77       41     69    33     229
  Baek et al. \[[@pone.0228857.ref053]\]          2009   51       91       116    9     111    91
  Yamamoto et al. \[[@pone.0228857.ref054]\]      2009   58       88       110    59    80     431
  Mao et al. \[[@pone.0228857.ref055]\]           2010   58       85       458    514   331    2914
  Ozkan et al. \[[@pone.0228857.ref056]\]         2010   83       95       62     4     13     79
  Bessa et al. \[[@pone.0228857.ref057]\]         2010   60       90       18     3     12     27
  Sharma et al. \[[@pone.0228857.ref058]\]        2010   73       66       51     13    19     25
  Ishida et al. \[[@pone.0228857.ref059]\]        2010   52       61       73     56    68     87
  Tian et al. \[[@pone.0228857.ref060]\]          2011   95       47       145    116   8      103
  Shi et al. \[[@pone.0228857.ref061]\]           2011   38       93       21     7     34     100
  Makarem et al. \[[@pone.0228857.ref062]\]       2011   74       100      84     0     29     120
  Morota et al. \[[@pone.0228857.ref063]\]        2011   63       91       44     3     26     31
  Salem et al. \[[@pone.0228857.ref064]\]         2012   90       78       27     9     3      31
  Shang-1 et al. \[[@pone.0228857.ref065]\]       2012   53       93       21     5     19     68
  Shang-2 et al. \[[@pone.0228857.ref065]\]       2012   78       96       71     1     20     22
  Yang et al. \[[@pone.0228857.ref066]\]          2013   37       85       66     12    113    68
  Choi et al. \[[@pone.0228857.ref067]\]          2013   79       85       71     12    19     66
  Ertle et al. \[[@pone.0228857.ref068]\]         2013   55       95       90     21    74     401
  Xu-1 et al. \[[@pone.0228857.ref069]\]          2014   69.74    91.18    1724   51    748    527
  Xu-2 et al. \[[@pone.0228857.ref069]\]          2014   51.58    97.75    1275   13    1197   565
  Xu-3 et al. \[[@pone.0228857.ref069]\]          2014   31.47    99.13    778    5     1694   573
  Chan-1 et al. \[[@pone.0228857.ref070]\]        2014   82.6     70.4     464    72    98     171
  Chan-2 et al. \[[@pone.0228857.ref070]\]        2014   47.7     97.1     268    7     294    236
  Chan-3 et al. \[[@pone.0228857.ref070]\]        2014   38.1     100      214    0     348    243
  Gopal-1 et al. \[[@pone.0228857.ref071]\]       2014   70.1     89.8     317    69    135    607
  Gopal-2 et al. \[[@pone.0228857.ref071]\]       2014   50       99.4     226    4     226    672
  Gopal-3 et al. \[[@pone.0228857.ref071]\]       2014   44       99.9     199    1     253    675
  Lee et al. \[[@pone.0228857.ref072]\]           2014   64       95       77     2     43     38
  Nabih et al. \[[@pone.0228857.ref073]\]         2014   49       91       17     3     18     31
  Song et al. \[[@pone.0228857.ref074]\]          2014   61       93       336    42    214    562
  Costa et al. \[[@pone.0228857.ref075]\]         2015   49       87       37     11    38     65
  Poté et al. \[[@pone.0228857.ref076]\]          2015   68       51       58     21    27     22
  Chang et al. \[[@pone.0228857.ref077]\]         2015   53       93       192    83    171    1151
  Gani et al. \[[@pone.0228857.ref078]\]          2015   73       92       43     4     16     43
  Chimparlee et al. \[[@pone.0228857.ref079]\]    2015   67       97       105    5     52     165
  Fouad et al. \[[@pone.0228857.ref080]\]         2015   100      100      25     0     0      25
  Ge et al. \[[@pone.0228857.ref081]\]            2015   72       88       64     36    25     265
  Yu et al. \[[@pone.0228857.ref082]\]            2015   77       65       103    121   31     226
  Jang et al. \[[@pone.0228857.ref083]\]          2016   62       90       129    19    79     174
  Roslyn et al. \[[@pone.0228857.ref084]\]        2016   43       97       37     9     49     249
  Ji et al. cohort A \[[@pone.0228857.ref085]\]   2016   68       81       160    26    76     109
  Ji et al. cohort B \[[@pone.0228857.ref085]\]   2016   62       69       124    30    76     67
  Ahn-1 et al. \[[@pone.0228857.ref086]\]         2016   50.55    87.7     185    45    181    321
  Ahn-2 et al. \[[@pone.0228857.ref086]\]         2016   37.7     95.9     138    15    228    351
  Ahn-3 et al. \[[@pone.0228857.ref086]\]         2016   30.05    97.27    110    10    256    356
  Ahn-4 et al. \[[@pone.0228857.ref086]\]         2016   24.04    98.36    88     6     278    360
  Lim et al. \[[@pone.0228857.ref087]\]           2016   56.8     82.8     205    47    156    229

SE: sensitivity; Sp: specificity; TP: true positive; FP: false positive; FN: false negative; TN: true negative.

Meta-analysis of diagnostic accuracy estimates {#sec008}
----------------------------------------------

As was shown in **[Table 3](#pone.0228857.t003){ref-type="table"}** and **Figs [2](#pone.0228857.g002){ref-type="fig"}--[4](#pone.0228857.g004){ref-type="fig"}**, four studies with AFP threshold of 400 ng/mL showed the summary sensitivity and specificity of 0.32 (95%CI 0.31--0.34) and 0.99 (95%CI 0.98--0.99), respectively, while eighteen studies with 400 ng/mL plus ultrasound showed the pooled sensitivity and specificity of 0.41 (95%CI 0.39--0.43) and 0.94 (95%CI 0.93--0.94), respectively. Four studies with AFP threshold of 200 ng/mL showed the summary sensitivity and specificity of 0.49 (95%CI 0.47--0.50) and 0.98 (95%CI 0.97--0.99), respectively, while eighteen studies with 200 ng/mL plus ultrasound showed the pooled sensitivity and specificity of 0.54 (0.52--0.55) and 0.94 (0.93--0.94), respectively. Forty-six studies with AFP threshold of 20--100 ng/mL showed the summary sensitivity and specificity of 0.61 (95%CI 0.60--0.62) and 0.86 (95%CI 0.86--0.87), respectively, while sixty studies eighteen studies with 20--100 ng/mL plus ultrasound showed the pooled sensitivity and specificity of 0.62 (0.61--0.63) and 0.88 (0.88--0.89), respectively.

![Forest plots of the estimates for AFP in HCC diagnosis (20--100 ng/mL).\
(A) Pooled sensitivity. (B) Pooled specificity. (C) Pooled positive LR. (D) Pooled negative LR.](pone.0228857.g002){#pone.0228857.g002}

![Forest plots of the estimates for AFP in HCC diagnosis (200 ng/mL).\
(A) Pooled sensitivity. (B) Pooled specificity. (C) Pooled positive LR. (D) Pooled negative LR.](pone.0228857.g003){#pone.0228857.g003}

![Forest plots of the estimates for AFP in HCC diagnosis (400 ng/mL).\
(A) Pooled sensitivity. (B) Pooled specificity. (C) Pooled positive LR. (D) Pooled negative LR.](pone.0228857.g004){#pone.0228857.g004}
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###### Diagnostic accuracy estimates based on varied thresholds of AFP.
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                Cut-off Value (ng/mL)                                                                                               
  ------------- ----------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------
  Sensitivity   0.61 (0.60--0.62)       0.62 (0.61--0.63)      0.49 (0.47--0.50)      0.54 (0.52--0.55)      0.32 (0.31--0.34)      0.41 (0.39--0.43)
  Specificity   0.86 (0.86--0.87)       0.88 (0.88--0.89)      0.98 (0.97--0.99)      0.94 (0.93--0.94)      0.99 (0.98--0.99)      0.94 (0.93--0.94)
  +LR           4.71 (4.47--4.98)       5.13 (4.89--5.38)      23.29 (16.65--32.57)   13.63 (11.86--15.67)   33.02 (20.34--53.6)    13.28 (11.59--15.23)
  -LR           0.47 (0.46--0.48)       0.44 (0.43--0.45)      0.54 (0.52--0.56)      0.43 (0.41--0.45)      0.67 (0.65--0.69)      0.50 (0.48--0.52)
  dOR           10.64 (9.91--11.42)     12.25 (11.46--13.10)   42.06 (29.88--59.20)   46.65 (37.62--57.84)   47.63 (29.22--77.64)   50.56 (39.58--64.58)
  AUC           0.8330                  0.8464                 0.9311                 0.9359                 0.9368                 0.9394
  SE(AUC)       0.0036                  0.0032                 0.0084                 0.0049                 0.0111                 0.0054
  Q\*           0.7654                  0.7778                 0.8664                 0.8723                 0.8734                 0.8767
  SE(Q\*)       0.0033                  0.0030                 0.0101                 0.0061                 0.0138                 0.0068

AFP alpha-fetoprotein, US ultrasound, +LR positive likelihood ratio, -LR negative likelihood ratio, dOR diagnostic odds ratio, AUC area under curve, SE standard error

The result from AFP alone as the marker indicated that the specificity of the threshold 400 ng/mL was the highest (99.0%), but the sensitivity was the lowest (32.0%). The specificity of the 200 ng/mL was 1.0% lower than that of the 400 ng/mL, but the sensitivity could increase to 49.0%, with dOR being the highest (42.06%). The threshold of 20--100 ng/mL owned the greatest sensitivity of 61.0%, but the specificity and dOR were lower than that of 200 ng/mL and 400 ng/mL.

Threshold identification by SROC analysis {#sec009}
-----------------------------------------

As is shown in **[Table 3](#pone.0228857.t003){ref-type="table"}** and **[Fig 5](#pone.0228857.g005){ref-type="fig"}**, The AUC of SROC and Q index of 400 ng/mL threshold were 0.9368 and 0.8734, respectively, which were significantly higher than those in 200 ng/mL threshold (0.9311 and 0.8664, respectively) and higher than those in 20-100ng/mL threshold (0.8330 and 0.7654, respectively). Similarly, when combined with ultrasound, the AUC of SROC and Q index of 400 ng/mL threshold were 0.9394 and 0.8767, respectively, which were significantly higher than those in 200 ng/mL threshold (0.9359 and 0.8723, respectively) and higher than those in 20--100 ng/mL threshold (0.8464 and 0.7778, respectively).

![Summary receiver operating characteristic curves (SROC).\
(A). SROC curve for AFP in 20--100 ng/mL. (B). SROC curve for AFP in 200 ng/mL. (C). SROC curve for AFP in 400 ng/mL. (D) SROC curve for AFP in 20--100 ng/mL combined with ultrasound. (E) SROC curve for AFP in 200 ng/mL combined with ultrasound. (F) SROC curve for AFP in 400 ng/mL combined with ultrasound.](pone.0228857.g005){#pone.0228857.g005}

Heterogeneity test and meta-regression analysis {#sec010}
-----------------------------------------------

There was no heterogeneity between groups of different threshold (p \> 0.05), as was shown in **[Table 4](#pone.0228857.t004){ref-type="table"}**. However, there existed heterogeneity in sensitivity, specificity, + LR, -LR and dOR within groups with varied threshold, as was shown in **[Table 5](#pone.0228857.t005){ref-type="table"}**. This heterogeneity may be related to the diversity of population selection, including hepatitis B (HBV) and hepatitis C (HCV), as well as some mixed cases, along with diverse detection methods, instruments, reagents, standards. However, only indicators of potential heterogeneity sources such as control, year, country, sample type, assay type and etiology (HBV, HCV or MIX) could be extracted from the included articles. The P-value \> 0.10 was realized as homogeneous \[[@pone.0228857.ref088]\], and no statistically significant effect existed on heterogeneity of three groups (P \> 0.10), as shown in **[Table 6](#pone.0228857.t006){ref-type="table"}**.

10.1371/journal.pone.0228857.t004

###### Spearman correlation analysis results.

![](pone.0228857.t004){#pone.0228857.t004g}

            Cut-off Value (ng/mL)                                 
  --------- ----------------------- ------- ------ ------- ------ -------
  Rs        0.22                    0.235   -0.6   0.482   -0.4   0.515
  p value   0.142                   0.071   0.4    0.043   0.6    0.029

AFP alpha-fetoprotein, US ultrasound, Rs rank correlation spearman

10.1371/journal.pone.0228857.t005

###### Chi-square test and Cochrane-Q test results.

![](pone.0228857.t005){#pone.0228857.t005g}

                    Cut-off Value (ng/mL)                                               
  ----------------- ----------------------- ---------- ---------- ---------- ---------- ----------
  **Sensitivity**                                                                       
  X^2^              573                     1020.46    61.26      648.00     40.63      937.09
  p value           \<0.0001                \<0.0001   \<0.0001   \<0.0001   \<0.0001   \<0.0001
  **Specificity**                                                                       
  X^2^              781.03                  1559.36    11.06      738.36     23.73      783.16
  p value           \<0.0001                \<0.0001   0.0114     \<0.0001   \<0.0001   \<0.0001
  **+LR**                                                                               
  Cochrane-Q        520.52                  934.42     12.88      737.99     27.12      716.93
  p value           \<0.0001                \<0.0001   0.0049     \<0.0001   \<0.0001   \<0.0001
  **-LR**                                                                               
  Cochrane-Q        726.99                  968.77     83.65      431.24     46.37      864.11
  p value           \<0.0001                \<0.0001   \<0.0001   \<0.0001   \<0.0001   \<0.0001
  **dOR**                                                                               
  Cochrane-Q        315.91                  460.09     16.95      127.94     22.75      138.79
  p value           \<0.0001                \<0.0001   0.0007     \<0.0001   \<0.0001   \<0.0001

+LR positive likelihood ratio, -LR negative likelihood ratio, dOR diagnostic odds ratio

10.1371/journal.pone.0228857.t006

###### Meta-regression analyses of potential source of heterogeneity.

![](pone.0228857.t006){#pone.0228857.t006g}

  Factors           Coeff.   Std. err.   P-value   RDOR
  ----------------- -------- ----------- --------- ------
  20--100 ng/ml                                    
      Year          0.077    0.1606      0.6339    1.08
      Country       0.062    0.0568      0.2819    1.06
      Control       0.195    0.1531      0.2097    1.22
      Sample type   0.030    0.2874      0.9169    1.03
      Etiology      0.120    0.1410      0.3986    1.13
      Assay type    0.022    0.2917      0.9409    1.02
  200 ng/ml                                        
      Country       -1.153   0.2972      0.1606    0.32
      Control       1.195    0.9167      0.4165    3.3
      Etiology      -0.403   0.8508      0.7183    0.67
  400 ng/ml                                        
      Country       -0.495   0.5226      0.5173    0.61
      Control       1.055    1.3062      0.5676    2.87
      Etiology      0.104    0.7493      0.9119    1.11

Coeff coefficient, RDOR ratio of the diagnostic odds ratio.

Publication bias {#sec011}
----------------

Deek's funnel plot showed a slope coefficient of 3.59 (p = 0.534), -42.60 (p = 0.666), -33.98 (p = 0.691) for included studies with 20--100, 200, 400 ng/mL, respectively, which indicated symmetry in data, where publication bias was not suggestive (**[S1](#pone.0228857.s005){ref-type="supplementary-material"}--[S3](#pone.0228857.s007){ref-type="supplementary-material"} Figs**, online supplement).

Discussion {#sec012}
==========

The disagreement between different international guidelines in terms of the AFP threshold for HCC diagnosis has been continued for several decades, and it has not yet been revolved so far. This article comprehensively reviewed the evidence for the threshold of AFP, and the results showed that AFP threshold of 400 ng/mL reporting the summary sensitivity of 0.32 (95%CI 0.31--0.34) and specificity of 0.99 (95%CI 0.98--0.99), was better than those of the threshold of 200 ng/mL (sensitivity of 0.49 (95%CI 0.47--0.50) and specificity of 0.98 (95%CI 0.97--0.99)), and better than those of the threshold of 20--100 ng/mL (sensitivity of 0.61 (95%CI 0.60--0.62) and specificity of 0.86 (95%CI 0.86--0.87)). The AUC of SROC and Q index of 400 ng/mL threshold were 0.9368 and 0.8734, respectively, which were significantly higher than those in 200 ng/mL threshold (0.9311 and 0.8664, respectively) and higher than those in 20--100 ng/mL threshold (0.8330 and 0.7654, respectively). Besides, similar result that favored 400 ng/mL were shown in the threshold in terms of AFP combined with ultrasound. The overall result indicated that the application of the AFP threshold of 400 ng/mL should be recommended for the diagnosis of HCC no matter it is used alone or combined with ultrasound to monitor the HCC.

It is well established that AFP level has been an optimal diagnostic marker for early diagnosis of HCC because of its well performance of sensitivity and specificity. However, along with HCC, there are other tumor contributors to the rise of AFP levels, such as reproductive system tumors; besides, the process of liver cell regeneration after an acute inflammation could also lead to the occurrence of a sharp increase in AFP levels during the progress of chronic liver diseases like hepatitis and liver cirrhosis\[[@pone.0228857.ref089]--[@pone.0228857.ref091]\]. Therefore, further laboratory examinations and imaging tests should be provided to combine the result of AFP to make a definite diagnosis \[[@pone.0228857.ref092], [@pone.0228857.ref093]\]. Because of this, the AFP threshold for the diagnosis of HCC is still controversial. AFP ≥ 400 ng/mL is recommended as the diagnostic criteria of HCC in the Chinese guideline for diagnosis and treatment of primary liver cancer (2017 edition) \[[@pone.0228857.ref094]\]. Nevertheless, Cedrone et al. \[[@pone.0228857.ref095]\] reported that the level of AFP in patients who had HCC was not affected by HBV or HCV, and a better threshold of serum AFP level should be 50 ng/mL. Another voice from Xu Jianye et al. \[[@pone.0228857.ref096]\] proposed that the 150 ng/mL diagnostic threshold of AFP for HCC showed better efficacy. Moreover, Zhang Jianhua et al. \[[@pone.0228857.ref020]\] proved that a low concentration of AFP in the range of 20--200 ng/mL could be used for early screening in the high risk population which could also be combined with ultrasound. However, the 2011 American Society of Hepatology HCC guidelines no longer use AFP as a screening method for HCC \[[@pone.0228857.ref097]\]. But what should draw our great attentions is the fact that unlike American, the major cause of HCC in other countries such as China is viral hepatitis, so that the dynamic surveillance of AFP level along with ultrasound in the screening among HCC high-risk population \[[@pone.0228857.ref098]\] still owns its great clinical application \[[@pone.0228857.ref099], [@pone.0228857.ref100]\]. What should actually be addressed in the next version guidelines of America, Europe, Asian-Pacific, and China, is the threshold of AFP in different phase in HCC management.

This meta analysis has its strengths and limitations. This systematic review included 59 articles and a total of 11,731 HCC cases and 21,972 non-HCC cases, which has summarized the evidence from the largest number of researches and participants representative of varied population from all over the world up to now. All the positive and negative cases in this review were confirmed by histomorphology, which ruled out the misclassification bias, and the quality of the included researches showed a low risk of bias. However, there is not without limitations. The articles in this meta analysis was restricted to the publications only in English language, which might missed the studies published in other languages. What is worth mentioning, in this review there are 20,732 cases from Asia, 630 cases from Africa, 5,924 cases from Europe, 8,666 cases from North America, which means that there might be selection bias when giving the conclusion of this article to the whole population; however, the results from meta-regression to detect the heterogeneity sources did not find any significant difference between countries. Furthermore, we have also detected considerable heterogeneity between three groups of varied threshold, and the meta-regression model has not discovered any heterogeneity resource with statistical significance. There also exists potential imbalance between the three groups of different threshold in terms of the number of the studies in each threshold group.

In conclusion, the present meta analysis suggests that AFP levels show good accuracy in HCC diagnosis, and the threshold of AFP with 400 ng/mL is better than that of 200 ng/mL and 20--100 ng/mL in terms of sensitivity and specificity no matter AFP is used alone or combined with ultrasound. Although included studies showed a low risk of bias, and publication bias was not suggestive, yet heterogeneity existed within groups, which might lead to the different threshold across geographic regions. Despite the current conclusion that AFP threshold of 400 ng/mL should be used for the diagnosis of HCC, the threshold of 20 ng/mL should also be suggested to lead to the decision to let a patient go into the surveillance program for HCC due to its high sensitivity. Future studies should pay more attention to the dynamic change of AFP along with the advance of HCC, where artificial intelligence might be applied to construct a model to predict the prognosis of HCC.

Materials and methods {#sec013}
=====================

This systematic review was performed according to the MOOSE and reported in accordance with PRISMA statement \[[@pone.0228857.ref027], [@pone.0228857.ref028]\]. The protocol was registered at PROSPERO (CRD42019133742, <http://www.crd.york.ac.uk/PROSPERO>).

Search strategy and article screening {#sec014}
-------------------------------------

The Medline and EMBASE databases were searched from inception up to November 2019 with the following terms: \"alpha-Fetoproteins or AFP\" AND \"Carcinoma, Hepatocellular or Hepatocellular Carcinomas or Liver Cell Carcinoma\" (The detailed search strategy was described in **[S1 Table](#pone.0228857.s002){ref-type="supplementary-material"}** and **[S2 Table](#pone.0228857.s003){ref-type="supplementary-material"}**). Besides, we reviewed the references in identified projects for further potential studies. Two reviewers independently screened the titles and abstracts of all retrieved records to find potentially appropriate studies, and then by reading the full text they evaluated the remaining records to identify studies suitable for data synthesis. Any disagreement was resolved by consensus or arbitrator.

Inclusion criteria {#sec015}
------------------

We finally included original articles that met the following criteria:

1.  Type of the study was diagnostic accuracy study.

2.  Participants in the study included both the patients with HCC diagnosed by pathological diagnosis (gold standard) were taken as the case group and the patients with clinically diagnosed non-liver cancer as the control group.

3.  Indicators to be evaluated in the study included AFP.

4.  There was a definite AFP measurement value in the article.

5.  Complete diagnostic four-grid table data could be obtained from the literature. (the indicators for HCC diagnosis should be directly or indirectly calculated or extracted, including true negative (TN) value, false negative (FN) value, false positive (FP)value, the true positive (TP) value, specificity, and sensitivity)

Exclusion criteria {#sec016}
------------------

1.  Non-English published studies.

2.  Conference abstracts, reviews, comments, opinions, letters, and editorials.

3.  Case reports, biochemical and experimental studies.

4.  The sample detected in the study was not plasma or serum.

Information extraction and quality assessment {#sec017}
---------------------------------------------

Basic information of each included studies was extracted by two reviewers independently. The QUADAS-2 was used to evaluate the quality of diagnostic test literature by two reviewers independently \[[@pone.0228857.ref029]\]. The evaluation tool includes three aspects---variation, bias, and report quality---and eleven items, where the answer of each item consists of three choices: \"Yes,\" \"No,\" and \"unclear.\" \"Yes\" means the study meet the criterion, \"No\" means not satisfied or not mentioned, and \"not clear\" is partially satisfied or unable to obtain sufficient information from the literature.

Data extraction and statistical processing {#sec018}
------------------------------------------

The diagnostic four-grid table data including TN, FN, FP, and TP were extracted from the included literatures, and Meta Disc 1.4 as well as Stata 15.0 software were used for statistical processing. The random effect model was applied to summarize the accuracy estimates if there was heterogeneity, while the fixed-effect model was applied if there was not. We calculated summary estimates of sensitivity, specificity, diagnostic odds ratio (dOR), positive likelihood ratio (+ LR), negative likelihood ratio (- LR). A summary receiver operating characteristic (SROC) curve was also displayed and the area under curve (AUC), and Q \* index was used to determine the threshold. Meta-analysis was used to obtain the combined value of the accuracy indicators and their 95%CI, The test level is α = 0.05. The heterogeneity caused by threshold effect was examined by Spearman correlation analysis, and sensitivity and specificity heterogeneity was examined by the chi-square test. The -LR and + LR were examined by Cochrane-Q test. Meta-regression analysis was used to detect the contributors of the heterogeneity. Deek's funnel plot was used to assess the publication bias, and a slope coefficient with p \<0.10 revealed significant bias.

Supporting information {#sec019}
======================
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